No Data
Verona Pharma Is Maintained at Buy by Canaccord Genuity
Verona Pharma Is Maintained at Buy by Canaccord
Express News | Verona Pharma PLC : Canaccord Genuity Raises Target Price to $37 From $35
Analysts Have Conflicting Sentiments on These Healthcare Companies: Astellas Pharma (OtherALPMF) and Verona Pharma (VRNA)
CCORF Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $37
CCORF analyst Edward Nash maintains $Verona Pharma(VRNA.US)$ with a buy rating, and adjusts the target price from $35 to $37.According to TipRanks data, the analyst has a success rate of 42.4% and a
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday; Set to End Week Down 4%
European equities traded in the US as American depositary receipts were trending modestly lower Friday, declining 0.37% to 1,410.60 on the S&P Europe Select ADR Index.The index is set to end the
European Equities Traded in the US as American Depositary Receipts Trend Lower Thursday
European equities traded in the US as American depositary receipts were moving moderately lower late Thursday morning, declining 0.72% to 1,423.26 on the S&P Europe Select ADR Index.From continental